Anti-EFGRv3 monoclonal antibody
AssigneeShanghai Cancer Institute
InventorsZonghai Li, Huamao Wang, Hua Jiang, Bizhi Shi, Jianren Gu, Shengli Yang
Life of this patent
Estimating the term…
Abstract
The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.
Claims9
A VH chain of monoclonal antibody, wherein its complementarity determining region CDR comprises the following amino acid sequences of CDRs:
- CDR1 as shown in SEQ ID NO:
- 5,
- CDR2 as shown in SEQ ID NO:
- 6, and
- CDR3 as shown in SEQ ID NO:
- 7.
A VL chain of monoclonal antibody, wherein its complementarity determining region CDR comprises the following amino acid sequences of CDRs:
- CDR1 as shown in SEQ ID NO:
- 8,
- CDR2 as shown in SEQ ID NO:
- 9, and
- CDR3 as shown in SEQ ID NO:
- 10.
A monoclonal antibody or its conjugate, wherein the amino acid sequences of its VH chain is as set out in SEQ ID NO:
- 2, and the amino acid sequences of its VL chain is as set out in SEQ ID NO:
- 4.
A DNA molecule, wherein it encodes the following protein selected from:
- a VH chain of a monoclonal antibody, wherein its complementarity determining region CDR comprises the following amino acid sequences of CDRs:
- CDR1 as shown in SEQ ID NO:
- 5,
- CDR2 as shown in SEQ ID NO:
- 6, and
- CDR3 as shown in SEQ ID NO:
- 7;
- a VL chain of a monoclonal antibody, wherein its complementarity determining region CDR selected from the following amino acid sequences of CDRs:
- CDR1 as shown in SEQ ID NO:
- 8,
- CDR2 as shown in SEQ ID NO:
- 9, and
- CDR3 as shown in SEQ ID NO:
- 10;
- a monoclonal antibody, wherein the amino acid sequences of its VH chain is as set out in SEQ ID NO:
- 2, and the amino acid sequences of its VL chain is as set out in SEQ ID NO:
- 4.
A pharmaceutical composition, wherein it comprises a monoclonal antibody and a pharmaceutically acceptable carrier, the VH chain of the said monoclonal antibody comprises the complementarity determining regions of SEQ ID NOs:
- 5-7 and the VL chain of the said monoclonal antibody comprises the complementarity determining regions of SEQ ID NO:8-10;
- or, the VH chain of the said monoclonal antibody comprises the amino acid sequence of SEQ ID NO:2, and the VL chain of the said monoclonal antibody comprises the amino acid sequence of SEQ ID NO:4.
Dependencies are inferred from the claim text.